Fonar Corp. (NASDAQ: FONR) Stock Competitors & Peer Comparison
See FONR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for FONR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FONR | $19.09 | +0.00% | 117.8M | 19.09 | $1.00 | N/A |
| SIRO | $109.97 | +0.00% | 22B | 31.88 | $3.45 | N/A |
| HIMS | $31.59 | +6.51% | 7B | -315.90 | -$0.10 | N/A |
| MMED | $19.60 | +6.41% | 5.5B | -25.29 | -$0.78 | N/A |
| OMCL | $36.81 | +1.80% | 1.7B | 19.27 | $1.91 | N/A |
| DRTS | $13.14 | +1.15% | 1.2B | -19.61 | -$0.67 | N/A |
| MLAB | $102.65 | +1.62% | 574.4M | 10.36 | $9.91 | +0.62% |
| LAB | $0.80 | -0.01% | 313.2M | -11.43 | -$0.07 | N/A |
| STXS | $1.42 | +4.41% | 139M | -8.35 | -$0.17 | N/A |
| LNSR | $6.04 | +5.32% | 74.2M | 6.16 | $0.98 | N/A |
Stock Comparison
Sirona Dental Systems, Inc. (NASDAQ: SIRO)
FONR vs SIRO Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas SIRO's P/E ratio is 31.88. In terms of profitability, FONR's ROE is +0.04%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, FONR is less volatile compared to SIRO. This indicates lower risk in terms of short-term price fluctuations for FONR.Check SIRO's competition here
Hims & Hers Health, Inc. (NYSE: HIMS)
FONR vs HIMS Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while HIMS trades at $31.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas HIMS's P/E ratio is -315.90. In terms of profitability, FONR's ROE is +0.04%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, FONR is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for FONR.Check HIMS's competition here
MiniMed Group, Inc. Common Stock (NASDAQ: MMED)
FONR vs MMED Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while MMED trades at $19.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas MMED's P/E ratio is -25.29. In terms of profitability, FONR's ROE is +0.04%, compared to MMED's ROE of -0.14%. Regarding short-term risk, FONR is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for FONR.Check MMED's competition here
Omnicell, Inc. (NASDAQ: OMCL)
FONR vs OMCL Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while OMCL trades at $36.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas OMCL's P/E ratio is 19.27. In terms of profitability, FONR's ROE is +0.04%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, FONR is less volatile compared to OMCL. This indicates lower risk in terms of short-term price fluctuations for FONR.Check OMCL's competition here
Alpha Tau Medical Ltd (NASDAQ: DRTS)
FONR vs DRTS Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while DRTS trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas DRTS's P/E ratio is -19.61. In terms of profitability, FONR's ROE is +0.04%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, FONR is less volatile compared to DRTS. This indicates lower risk in terms of short-term price fluctuations for FONR.Check DRTS's competition here
Mesa Laboratories, Inc. (NASDAQ: MLAB)
FONR vs MLAB Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while MLAB trades at $102.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas MLAB's P/E ratio is 10.36. In terms of profitability, FONR's ROE is +0.04%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, FONR is less volatile compared to MLAB. This indicates lower risk in terms of short-term price fluctuations for FONR.Check MLAB's competition here
Standard BioTools Inc. (NASDAQ: LAB)
FONR vs LAB Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while LAB trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas LAB's P/E ratio is -11.43. In terms of profitability, FONR's ROE is +0.04%, compared to LAB's ROE of -0.18%. Regarding short-term risk, FONR is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for FONR.Check LAB's competition here
Stereotaxis, Inc. (AMEX: STXS)
FONR vs STXS Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, STXS has a market cap of 139M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while STXS trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas STXS's P/E ratio is -8.35. In terms of profitability, FONR's ROE is +0.04%, compared to STXS's ROE of -1.53%. Regarding short-term risk, FONR is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for FONR.Check STXS's competition here
LENSAR Inc (NASDAQ: LNSR)
FONR vs LNSR Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while LNSR trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas LNSR's P/E ratio is 6.16. In terms of profitability, FONR's ROE is +0.04%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, FONR is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for FONR.Check LNSR's competition here
Kindly MD, Inc. (NASDAQ: KDLY)
FONR vs KDLY Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas KDLY's P/E ratio is -15.48. In terms of profitability, FONR's ROE is +0.04%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, FONR is less volatile compared to KDLY. This indicates lower risk in terms of short-term price fluctuations for FONR.Check KDLY's competition here
NeueHealth, Inc. (NYSE: NEUE)
FONR vs NEUE Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas NEUE's P/E ratio is -0.38. In terms of profitability, FONR's ROE is +0.04%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, FONR is less volatile compared to NEUE. This indicates lower risk in terms of short-term price fluctuations for FONR.Check NEUE's competition here
SANUWAVE Health Inc. (NASDAQ: SNWV)
FONR vs SNWV Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while SNWV trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas SNWV's P/E ratio is 17.82. In terms of profitability, FONR's ROE is +0.04%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, FONR is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for FONR.Check SNWV's competition here
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)
FONR vs EKSO Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while EKSO trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas EKSO's P/E ratio is -3.11. In terms of profitability, FONR's ROE is +0.04%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, FONR is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for FONR.Check EKSO's competition here
HeartBeam, Inc. (NASDAQ: BEAT)
FONR vs BEAT Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while BEAT trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas BEAT's P/E ratio is -0.94. In terms of profitability, FONR's ROE is +0.04%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, FONR is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for FONR.Check BEAT's competition here
Sharps Technology Inc. Wt (NASDAQ: STSSW)
FONR vs STSSW Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas STSSW's P/E ratio is -0.03. In terms of profitability, FONR's ROE is +0.04%, compared to STSSW's ROE of N/A. Regarding short-term risk, FONR is similarly volatile compared to STSSW. This indicates similar risk in terms of short-term price fluctuations for FONR.Check STSSW's competition here
Span-America Medical Systems, Inc. (NASDAQ: SPAN)
FONR vs SPAN Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas SPAN's P/E ratio is N/A. In terms of profitability, FONR's ROE is +0.04%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, FONR is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for FONR.Check SPAN's competition here
Exactech, Inc. (NASDAQ: EXAC)
FONR vs EXAC Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, FONR's ROE is +0.04%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, FONR is similarly volatile compared to EXAC. This indicates similar risk in terms of short-term price fluctuations for FONR.Check EXAC's competition here
Advisory Board Co. (The) (NASDAQ: ABCO)
FONR vs ABCO Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, ABCO has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas ABCO's P/E ratio is 0.52. In terms of profitability, FONR's ROE is +0.04%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, FONR is less volatile compared to ABCO. This indicates lower risk in terms of short-term price fluctuations for FONR.Check ABCO's competition here
Surgical Care Affiliates, Inc. (NASDAQ: SCAI)
FONR vs SCAI Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, SCAI has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas SCAI's P/E ratio is 63.45. In terms of profitability, FONR's ROE is +0.04%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, FONR is less volatile compared to SCAI. This indicates lower risk in terms of short-term price fluctuations for FONR.Check SCAI's competition here
Landauer Inc. (NYSE: LDR)
FONR vs LDR Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, LDR has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas LDR's P/E ratio is N/A. In terms of profitability, FONR's ROE is +0.04%, compared to LDR's ROE of +1.17%. Regarding short-term risk, FONR is less volatile compared to LDR. This indicates lower risk in terms of short-term price fluctuations for FONR.Check LDR's competition here
Mazor Robotics Ltd. (NASDAQ: MZOR)
FONR vs MZOR Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, MZOR has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas MZOR's P/E ratio is -70.18. In terms of profitability, FONR's ROE is +0.04%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, FONR is similarly volatile compared to MZOR. This indicates similar risk in terms of short-term price fluctuations for FONR.Check MZOR's competition here
Med-Design Corp. (The) (NASDAQ: MEDC)
FONR vs MEDC Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas MEDC's P/E ratio is N/A. In terms of profitability, FONR's ROE is +0.04%, compared to MEDC's ROE of N/A. Regarding short-term risk, FONR is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for FONR.Check MEDC's competition here
St. Jude Medical, Inc. (NYSE: STJ)
FONR vs STJ Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, STJ has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas STJ's P/E ratio is 34.69. In terms of profitability, FONR's ROE is +0.04%, compared to STJ's ROE of +0.21%. Regarding short-term risk, FONR is less volatile compared to STJ. This indicates lower risk in terms of short-term price fluctuations for FONR.Check STJ's competition here
LifePoint Health, Inc. (NASDAQ: LPNT)
FONR vs LPNT Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, LPNT has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas LPNT's P/E ratio is 67.44. In terms of profitability, FONR's ROE is +0.04%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, FONR is similarly volatile compared to LPNT. This indicates similar risk in terms of short-term price fluctuations for FONR.Check LPNT's competition here
Cynosure, Inc. (NASDAQ: CYNO)
FONR vs CYNO Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, CYNO has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas CYNO's P/E ratio is 105.35. In terms of profitability, FONR's ROE is +0.04%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, FONR is less volatile compared to CYNO. This indicates lower risk in terms of short-term price fluctuations for FONR.Check CYNO's competition here
Pharmerica Corporation (NYSE: PMC)
FONR vs PMC Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, PMC has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas PMC's P/E ratio is 47.95. In terms of profitability, FONR's ROE is +0.04%, compared to PMC's ROE of +0.04%. Regarding short-term risk, FONR is less volatile compared to PMC. This indicates lower risk in terms of short-term price fluctuations for FONR.Check PMC's competition here
Abaxis, Inc. (NASDAQ: ABAX)
FONR vs ABAX Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, ABAX has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while ABAX trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas ABAX's P/E ratio is 70.62. In terms of profitability, FONR's ROE is +0.04%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, FONR is similarly volatile compared to ABAX. This indicates similar risk in terms of short-term price fluctuations for FONR.Check ABAX's competition here
Envision Healthcare Corporation (NYSE: EVHC)
FONR vs EVHC Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, EVHC has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas EVHC's P/E ratio is -3.20. In terms of profitability, FONR's ROE is +0.04%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, FONR is less volatile compared to EVHC. This indicates lower risk in terms of short-term price fluctuations for FONR.Check EVHC's competition here
Cotiviti Holdings, Inc. (NYSE: COTV)
FONR vs COTV Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, COTV has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas COTV's P/E ratio is 26.51. In terms of profitability, FONR's ROE is +0.04%, compared to COTV's ROE of +0.14%. Regarding short-term risk, FONR is less volatile compared to COTV. This indicates lower risk in terms of short-term price fluctuations for FONR.Check COTV's competition here
AmSurg Corp (NASDAQ: AMSG)
FONR vs AMSG Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, AMSG has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas AMSG's P/E ratio is N/A. In terms of profitability, FONR's ROE is +0.04%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, FONR is less volatile compared to AMSG. This indicates lower risk in terms of short-term price fluctuations for FONR.Check AMSG's competition here
Spectranetics Corp. (The) (NASDAQ: SPNC)
FONR vs SPNC Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, SPNC has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas SPNC's P/E ratio is -24.03. In terms of profitability, FONR's ROE is +0.04%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, FONR is less volatile compared to SPNC. This indicates lower risk in terms of short-term price fluctuations for FONR.Check SPNC's competition here
Derma Sciences, Inc. (NASDAQ: DSCI)
FONR vs DSCI Comparison August 2026
Fonar Corp. (NASDAQ: FONR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FONR stands at 117.8M. In comparison, DSCI has a market cap of 0. Regarding current trading prices, FONR is priced at $19.09 on the NASDAQ, while DSCI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FONR currently has a P/E ratio of 19.09, whereas DSCI's P/E ratio is -0.02. In terms of profitability, FONR's ROE is +0.04%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, FONR is less volatile compared to DSCI. This indicates lower risk in terms of short-term price fluctuations for FONR.Check DSCI's competition here